<DOC>
	<DOCNO>NCT01682746</DOCNO>
	<brief_summary>The goal proposal evaluate new Photodynamic Therapy ( PDT ) modification could revolutionize treatment brain tumor child adult . There currently case publish involve use PDT infratentorial ( posterior fossa ) brain tumor general specifically occur child . The investigator propose test technique , first time U.S. , demonstrate Australian adult glioblastoma patient dramatic long-term , survival rate 57 % ( anaplastic astrocytoma ) 37 % ( glioblastoma multiforme ) . These result unprecedented treatment protocol . Photodynamic therapy ( PDT ) paradigm shift treatment tumor traditional resection systemic chemotherapy method . The principle behind photodynamic therapy light-mediated activation photosensitizer selectively accumulate target tissue , cause tumor cell destruction singlet oxygen production . Therefore , photosensitizer consider first critical element PDT procedure , activation procedure second step . The methodology use proposal utilizes intensive laser light large Photofrin photosensitizer dose prior PDT protocol U.S. brain tumor patient . The PDT consist photoillumination 630 nm begin center tumor resection cavity , deliver total energy 240 J cm−2 . The investigator feel light penetrate far enough tissue reach migrate tumor cell , destroy cell without harm healthy cell disperse . The investigator test hypothesis pediatric subject progressive/recurrent malignant brain tumor undergoing PDT increase dos Photofrin® light energy use previous clinical study show good progression free survival ( PFS ) overall survival ( OS ) outcomes . PDT also effective infratentorial tumor . The specific aim include determine maximum tolerable dose ( MTD ) Photofrin child look preliminary effectiveness trend .</brief_summary>
	<brief_title>Photodynamic Therapy ( PDT ) Recurrent Pediatric Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Dihematoporphyrin Ether</mesh_term>
	<mesh_term>Hematoporphyrin Derivative</mesh_term>
	<mesh_term>Trioxsalen</mesh_term>
	<criteria>1 . Age : ≥ 6 month &lt; 18 year 2 . Disease : Patients relapse refractory brain tumor eligible . Patients must histologic verification malignancy original diagnosis relapse . Tumors either supratentorial infratentorial ( posterior fossa ) location . 3 . Disease Status : Patients must potentially resectable disease . 4 . Therapeutic Options : Patients ' current disease state must one know curative therapy therapy proven prolong survival acceptable quality life . 5 . Performance Level : Karnofsky 50 % great patient &gt; 16 year age Lansky 50 great patient &lt; 16 year age . Note : Neurologic deficit patient CNS tumor must relatively stable least 7 day prior study enrollment . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . 6 . Predictable Life Expectancy : &gt; 8 week 7 . Prior Therapy : Patients must fully recover acute toxic effect prior anticancer chemotherapy . At least 3 week previous chemotherapy 4 week prior radiation therapy 8 . Organ Function : Adequate bone marrow function Absolute neutrophil count ≥ 1,000 Platelet count ≥ 100,000 ( may transfuse meet requirement ) Adequate renal function Creatinine clearance radioisotope GFR ≥ 70 mL/min/1.73 m2 OR A serum creatinine within normal range base age/gender Adequate liver function Bilirubin ( direct ) ≤ 3X upper limit normal ( ULN ) age SGPT ( ALT ) ≤ 10X ULN For purpose study , ULN SGPT 45 U/L Serum albumin ≥ 2 g/dL Adequate coagulation PT INR ≤ 2X ULN age 9 . Central Nervous System Function : Patients seizure disorder may enrol receive non enzyme induce anticonvulsant well control . 10 . Informed Consent : All patient and/or parent legally authorize representative must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . 11 . Archival tumor tissue slide initial diagnosis review CHW institutional pathologist prior study enrollment whenever possible . Exclusion Criteria 1 . Disseminated disease ( metastatic disease ) 2 . Pregnancy BreastFeeding : Pregnant breastfeed woman enter study , risk fetal teratogenic adverse effect Photofrin® know . 3 . Other concurrent tumor therapy 4 . Subjects porphyria 5 . Subjects take potentially photosensitize drug 6 . The presence adverse event neurologic function , photosensitivity , photophobia Grade 4 high ( CTCAE Version 4.0 ) 7 . Allergy egg , soybean oil , safflower oil ( due potential allergy intralipids ) 8 . Patients opinion investigator may able comply safety monitoring requirement study eligible .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Brain Tumor</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Photochemotherapy</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Pilocytic Astrocytoma</keyword>
	<keyword>Low grade Astrocytoma</keyword>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Chordoma</keyword>
	<keyword>Germinoma</keyword>
	<keyword>Germ Cell Tumor</keyword>
	<keyword>Non-germinaoma</keyword>
	<keyword>CNS Lymphoma</keyword>
	<keyword>Craniopharyngioma</keyword>
	<keyword>Brain Stem Glioma</keyword>
	<keyword>Ependymoma</keyword>
	<keyword>Mixed Glioma</keyword>
	<keyword>Optic Nerve Glioma</keyword>
	<keyword>Subependymoma</keyword>
	<keyword>Medulloblastoma</keyword>
	<keyword>Meningioma</keyword>
	<keyword>Metastatic Brain Tumors</keyword>
	<keyword>Oligodendroglioma</keyword>
	<keyword>Pituitary Tumors</keyword>
	<keyword>Primitive Neuroectodermal</keyword>
	<keyword>PNET</keyword>
	<keyword>Desmoplastic Neuroepithelial Tumor</keyword>
	<keyword>DNET</keyword>
</DOC>